{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457119710
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[IGF-1 receptor]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  Experimental
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 943453-46-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = VE267FC2UB
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09345
<!-- Chemical data -->
| C=6462 | H=9948 | N=1736 | O=2020 | S=54
| molecular_weight = 146.0 kg/mol
}}
'''Figitumumab''' (previously CP-751871) is a [[monoclonal antibodies|monoclonal antibody]]<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/figitumumab.pdf Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab], ''American Medical Association''.</ref> targeting the [[insulin-like growth factor-1 receptor]] that was investigated for the treatment of various types of [[cancer]], for example [[adrenocortical carcinoma]]<ref>{{cite journal|pmid=19649631|year=2009|last1=Haluska|first1=P|last2=Worden|first2=F|last3=Olmos|first3=D|last4=Yin|first4=D|last5=Schteingart|first5=D|last6=Batzel|first6=GN|last7=Paccagnella|first7=ML|last8=De Bono|first8=JS|last9=Gualberto|first9=A|last10=Hammer|first10=Gary D.|title=Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma|doi=10.1007/s00280-009-1083-9|journal=Cancer chemotherapy and pharmacology|volume=65|issue=4|pages=765–773|pmc=2875253|display-authors=8}}</ref> and [[non-small cell lung cancer]] (NSCLC).<ref>{{cite journal|pmid=19632947|year=2009|last1=Gualberto|first1=A|last2=Karp|first2=DD|title=Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer|volume=10|issue=4|pages=273–80|doi=10.3816/CLC.2009.n.038|journal=Clinical Lung Cancer}}</ref>

This drug was being developed by [[Pfizer]], but they ceased development of the drug in January 2011 and has stopped its manufacture.<ref>{{cite news|url=http://www.bbc.co.uk/news/health-28293678|date=July 2014|title=Cancer sufferer fears future without 'life-saver' drug|work=BBC News}}</ref>

==Anti-cancer mechanism==
See [[Insulin-like growth factor 1 receptor#Role in cancer|Insulin-like growth factor 1 receptor role in cancer]].

==Clinical trials==
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths<ref>{{cite news|url=https://www.reuters.com/article/idUSTRE5BS3XY20091229|publisher=Reuters|title=Pfizer ends late-stage lung-cancer study|date=29 December 2009 | first=Lewis | last=Krauskopf}}</ref> but others continued.<ref>{{ClinicalTrialsGov|NCT00976508|Figitumumab Combined With Pegvisomant For Advanced Solid Tumors}}</ref><ref>{{ClinicalTrialsGov|NCT00635245|CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery}}</ref>

It was to have been included in the I-SPY2 [[breast cancer]] trial.<ref>{{cite news|url=https://www.reuters.com/article/idUSN1612347120100317|publisher=Reuters|title=Breast cancer study aims to speed drugs, cooperation|date= March 2010}}</ref>

== References ==
<references/>

{{Monoclonals for tumors}}
{{Growth factor receptor modulators}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Pfizer]]
[[Category:Abandoned drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}